Related Experiment Video

Updated: May 20, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Protein kinase A alterations in endocrine tumors

B Yu1, B Ragazzon, M Rizk-Rabin

  • 1Institut Cochin, INSERM U1016, Paris, France.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|July 4, 2012
PubMed

Insights

Alterations in protein kinase A (PKA) regulatory subunits, particularly PRKAR1A, are linked to endocrine tumors like Carney complex. These mutations can lead to tumor development by affecting the cyclic adenosine monophosphate (cAMP) pathway.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • The cyclic adenosine monophosphate (cAMP) pathway is frequently altered in endocrine tumors.
  • Protein kinase A (PKA), a key component of the cAMP pathway, has shown alterations in its regulatory subunits, primarily PRKAR1A.
  • Carney complex (CNC) serves as a prime example, often involving endocrine gland manifestations due to PRKAR1A mutations.

Purpose of the Study:

  • To investigate the role of PKA subunit alterations in endocrine tumor development.
  • To elucidate the mechanisms underlying cAMP pathway dysregulation in human diseases.
  • To explore the implications of PRKAR1A mutations in both hereditary and sporadic endocrine tumors.

Main Methods:

  • Analysis of molecular and cellular alterations in PKA subunits within endocrine tumors.
  • Genetic studies identifying germline and somatic mutations in PRKAR1A.
  • In vitro and in vivo functional studies to assess the impact of mutations on PKA activity and tumor development.

Main Results:

  • PRKAR1A mutations are found in approximately two-thirds of Carney complex patients and isolated primary pigmented nodular adrenocortical disease (PPNAD).
  • PRKAR1A functions as a tumor suppressor gene, with over 120 identified mutations.
  • Most PRKAR1A mutations result in unstable mRNA, leading to degradation via nonsense-mediated decay, and often stimulate PKA activity, mimicking constitutive cAMP pathway activation.

Conclusions:

  • PRKAR1A mutations are significant drivers of endocrine tumorigenesis, particularly in CNC and PPNAD.
  • Understanding PKA subunit inactivation mechanisms is crucial for deciphering endocrine tumor development.
  • Cross-talks with other signaling pathways may also contribute to endocrine tumor formation.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...